NASDAQ: HOTHHoth Therapeutics Inc Stock Ownership - Who owns Hoth Therapeutics?
Insider buying vs selling
Have Hoth Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Robb Knie | CEO and President | 2024-08-16 | 25,000 | $0.67 | $16.75kBuy |
HOTH insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when HOTH insiders and whales buy or sell their stock.
HOTH Shareholders
What type of owners hold Hoth Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Anthony Hayes | 24.99% | 3,300,516 | $4.29M | Insider |
| Aikido Pharma Inc | 8.56% | 1,130,674 | $1.47M | Insider |
| Kenneth L. Rice Jr. | 5.88% | 776,943 | $1.01M | Insider |
| Matthew D. Eitner | 5.68% | 750,000 | $975.00k | Insider |
| Kevin Jess Poor | 5.68% | 750,000 | $975.00k | Insider |
| James P. Ahern | 5.68% | 750,000 | $975.00k | Insider |
| Geode Capital Management LLC | 0.86% | 113,504 | $147.56k | Institution |
| Ubs Group Ag | 0.44% | 58,758 | $76.39k | Institution |
| Robb Knie | 0.44% | 58,131 | $75.57k | Insider |
| Vanguard Group Inc | 0.29% | 38,804 | $50.45k | Institution |
HOTH vs Biotech Stocks
Hoth Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.